|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1.** Sociodemographic and clinical characteristics of the study sample consisting of two groups: patients receiving a co-treatment with sertraline and clozapine (SERTCLZ) and a matched control group receiving sertraline, but no clozapine (SERT). | | | | | | | | |
| Characteristics | SERTCLZ (n=15) | | | SERT (n=17) | | | Comparison | |
|  | Median | Q1 | Q3 | Median | Q1 | Q3 | Rank sum | p |
| age [years] | 36 | 24 | 49 | 36 | 25 | 49 | 240.0 | 0.790 |
| dose of sertraline [mg / day] | 125 | 56 | 150 | 150 | 100 | 150 | 215.5 | 0.216 |
| weight [kg] | 81 | 77 | 120 | 80 | 76 | 101 | 274.5 | 0.311 |
|  | n | % | | n | % | | χ2 (df = 1) | p |
| sex |  |  |  |  |  |  | 0.03 | 0.863 |
| female | 4 | 26.7 | | 5 | 29.4 | |  |  |
| male | 11 | 73.3 | | 12 | 70.6 | |  |  |
| nicotine consumption |  |  |  |  |  |  | 0.43 | 0.513 |
| smokers | 7 | 46.7 | | 6 | 35.3 | |  |  |
| non-smokers | 8 | 53.3 | | 11 | 64.7 | |  |  |
| caffeine consumption |  |  |  |  |  |  | 1.21 | 0.272 |
| consumers | 13 | 86.7 | | 12 | 70.6 | |  |  |
| non-consumers | 2 | 13.3 | | 5 | 29.4 | |  |  |